TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced that an abstract highlighting data supporting ...
The full abstract will be published online on April 25, 2025. More details about the programs for the AACR Annual Meeting 2025 are available online at AACR Annual Meeting 2025 | Meetings | AACR.
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced that an ...